Uterine Fibroids Treatment
Europe · 1 shared keyword
Updated
Reviewed by Vidhi Upadhyay
Europe Sedation Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$245.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $653.5 Mn | — | — |
| 2025 (base) | $676.4 Mn | +$22.9 Mn | — |
| 2026 (forecast) | $700.0 Mn | +$23.7 Mn | +3.5% |
| 2027 (forecast) | $724.5 Mn | +$24.5 Mn | +7.1% |
| 2028 (forecast) | $749.9 Mn | +$25.4 Mn | +10.9% |
| 2029 (forecast) | $776.2 Mn | +$26.2 Mn | +14.8% |
| 2030 (forecast) | $803.3 Mn | +$27.2 Mn | +18.8% |
| 2031 (forecast) | $831.4 Mn | +$28.1 Mn | +22.9% |
| 2032 (forecast) | $860.5 Mn | +$29.1 Mn | +27.2% |
| 2033 (forecast) | $890.7 Mn | +$30.1 Mn | +31.7% |
| 2034 (forecast) | $921.8 Mn | +$31.2 Mn | +36.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $676.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $921.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 3.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Sedative-Hypnotic Drugs |
| Segments | Drug, setting and end user (see all) |
| Key players | Fresenius Kabi AG, Pfizer Inc., Hikma Pharmaceuticals PLC, Acacia Pharma (Eagle), Baxter International (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Sedation drugs calm patients during procedures and in intensive care, such as propofol, dexmedetomidine and midazolam.
Key segments of the sedation Drugs market include drug (Propofol, Dexmedetomidine and Midazolam) and setting (ICU, Procedural Sedation and Surgery).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the sedation Drugs market.
Ready-to-use formulations, biosimilars and supply security programmes give the sedation Drugs market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the sedation Drugs market.
The sedation Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.
[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.
[10] Swissmedic. Checked 19 Nov 2026.
[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.
[12] Danish Medicines Agency. Checked 19 Nov 2026.
[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.
[15] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sedation Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Sedation Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe
Europe
Europe
Digital Health · Europe
Digital Health · Europe
Medical Devices · Europe
Medical Devices · Europe
Medical Devices · Europe
Healthcare Services · Europe